Welcome to our dedicated page for Kiniksa Pharmaceuticals International news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International stock.
Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a public offering of 1,800,000 Class A common shares, with an additional 270,000 shares available to underwriters. The net proceeds will support the clinical development of its product candidates, fund R&D activities, and cover general corporate purposes. Goldman Sachs, J.P. Morgan, and BofA Securities are managing the offering. Kiniksa emphasizes that the offering's details are included in the SEC registration statement, which should be reviewed before investing.
The press release from Kiniksa Pharmaceuticals, Ltd. highlights positive clinical results from two investigational treatments: mavrilimumab and vixarelimab. Mavrilimumab demonstrated improved outcomes in severe COVID-19 pneumonia patients, with 85% achieving clinical improvement by day 14, significantly outperforming the control group. Vixarelimab showed promising efficacy in chronic pruritus diseases, particularly plaque psoriasis, achieving a statistically significant reduction in itch severity. Kiniksa plans further development for both drugs, including potential registrational studies for mavrilimumab.
Summary not available.